Introduction: Acute myocardial infarction is the most important and feared consequence of coronary artery disease. STEMI is the one of that kind and it occurs by formation of a vulnerable plaque from atherosclerosis and transforms into coronary artery thrombosis in the end. Streptokinase has been used as a thrombolytic agent in patients with acute STEMI. It combines with the circulatory plasminogen to form an activator complex and it converts into plasmin, where, the plasmin breaks the fibrin complex in the blood clot. Streptokinase can be given as 1,500,000U a slow I.V infusion over 30 min. Each STEMI subject is different with the aetiology, pain, ST segment elevation. By considering these factors the clinical efficacy of streptokinase will be evaluated. Materials and Methods: A total number of 75 subjects presenting with acute STEMI to the department of cardiology, King George Hospital, Visakhapatnam, and, those were thrombolysed with streptokinase are included in the study. pain was assessed before and 90 min after administration of streptokinase on numerical pain rating scale from 0-10. ST segment resolution was assessed as percentage reduction in ST segment elevation before administration of streptokinase and the reduction of ST segment elevation 90 min after administration of streptokinase. Student t-test and chi-square test were applied to evaluate the results by using software SPSS. Results: A significant resolution in the pain and ST segment elevation were identified by comparing the numerical pain rating scale and ST segment elevation on pre and post streptokinase administration. Conclusion: Streptokinase has been shown to have significant effect on pain resolution and ST segment resolution in subjects with acute ST segment elevation myocardial infarction.
INTRODUCTION
Cardiovascular disease has emerged as the single most important cause of death worldwide over the past decade and its frequency is increasing. Acute coronary syndromes form the most important component of the CVD for the sake of immediate treatment strategies such as reperfusion therapies. ACS has been classified as STEMI and NSTEMI. STEMI occurs when a result in complete occlusion of a major epicardial artery. The most effective treatment for STEMI immediately restoring the patency of the occluded artery either by PCI or fibrinolysis. 1 Fibrinolysis is an important reperfusion strategy in settings where primary PCI cannot be offered immediately to a patient due to unavailability of a cath lab and trained personal. Fibrinolysis prevents nearly 30 early deaths of 1000 patients when they are treated within 6 h of symptoms onset. Streptokinase is a non-fibrin selective fibrinolytic that acts as occluding thrombus and lysis to restore the patency of the epicardial artery. The study has been undertaken to assess the clinical efficacy of streptokinase, administered in patients presenting with acute STEMI and window period ≤ 12 h to the Department of Cardiology, KGH, Visakhapatnam.
MATERIALS AND METHODS
The present study is a prospective observational study conducted during February 2016-August 2016, in King George Hospital, Visakhapatnam which is a 1400 bedded tertiary care medical college hospital. The department of cardiology in King George Hospital established in 1970 was the study site. It is a 70 bedded department providing state of art, cardiac care to the patients of north coastal Andhra. Institutional Ethics Committee of King George Hospital gave the clearance to carry out the study and the study was executed. The study subjects consisted of the patients who were admitted in the department of cardiology during the period of February 2016 to August 2016. The inclusion criteria and exclusion criteria mentioned in the study protocol was strictly followed. All the patients admitted with acute STEMI and thrombolysed with streptokinase, during the study period who had consented for participation were included. The subjects who were not thrombolysed with streptokinase and those who did not give their consent were not included. The study subjects were interviewed and the details were recorded in the pro forma. Information related to window period, risk factors of CAD (diabetes mellitus, hypertension, smoking, alcohol, Body Mass Index, Family History) was recorded. Height, weight, blood pressure and heart rate of the subjects was recorded. Information related to diet consumption was also captured. Investigation reports of relevant blood parameter RBS was recorded. ECG of all the subjects was taken before the administration of streptokinase and 90 min after administration of streptokinase. Perception of pain was recorded using Numerical Pain Rating Scale before administration of streptokinase and 90 min after administration of streptokinase. Data from all the pro forma was entered in to a template created in Microsoft excel 2016 and statistical analysis was done using SPSS version 17.
RESULTS
The study group consisted of 75 subjects who included 59 (78.7%) males and 16 (21.3%) female subjects. The mean age of male subjects was 54 years and the female subjects were 56.625 years. Majority of the study subjects consumed mixed diet 90.67% and only 9.33% were vegetarians. Among the study subjects 37.33% were diabetics, 44% were hypertensive, 41.33% were smokers, 36% were alcoholics and 20% were overweight and obese subjects. Further 21.33% of study subjects had a family history of CAD ( Figure 1 ). The association between pain perception before streptokinase administration and 90 min after streptokinase administration with risk factors (Table. 1 ). The association between ST segment elevation before streptokinase administration and 90 min after streptokinase administration with risk factors (Table. 2).
DISCUSSION
The major aim of this study is to find out the clinical efficacy of streptokinase. The study conducted mainly based on changes in ST segment elevation and the numerical pain rating scale, before administration of streptokinase and 90 min after administration of streptokinase. In the present study, a total of 75 subjects with acute STEMI and those were thrombolysed with streptokinase was considered. All risk factors of CAD also included and evaluated. Streptokinase is the widely used, most feasible and primary treatment option for STEMI in King George Hospital. Likewise, a study by Ruwanthi handava, Arjun Medagama et al., they have also found that, thrombolysis is the primary treatment option for STEMI in Srilanka tertiary care hospital. 2 Based on global studies, thrombolysis with streptokinase is the common and standalone treatment of reperfusion and it gives less haemorrhagic complication and reduces the risk of stroke as compared with other thrombolytics. 3 Many other global studies on Streptokinase efficacy also demonstrated conclusively that, streptokinase is the safest, economically feasible, reduces STEMI complications and mortality rate. [4] [5] [6] According to the Brendon J smith comparative study on streptokinase with t-PA, the study concluded that streptokinase can be considered the thrombolytic agent of choice. 7 In overall study, the window period was reported up to ≤ 12 h, but higher resolution was noted 0-4 h window period, which is not statistically significant due to less population noted in the period of six months. In a study, conducted by Dr. Girish Ronad and Dr. Rohit present in Gulbarga, India, similar results were obtained. Higher success rate with thrombolysis was seen with window period between 0-4 hrs in the above study. They have found no significant association between frequency of thrombolysis and baseline risk factors. 8 Although irrespective of the window period, in some subjects the drug streptokinase has shown its efficacy in both pain and ST segment resolution after 4 h of window period, in accordance with Ulhas Jajoo, Bharathi taskande et al. they have also demonstrated that relief in ongoing coronary pain uniformly distributed irrespective of time lag of streptokinase infusion. 9 When our study compared the pain NPRS between before administration of streptokinase (±8.95) and 90 min after administration of streptokinase (±1.41), the mean score of pain was reduced tremendously after thrombolysis and those results are statistically significant (p<0.0001) (Figure 2 ). Same as in the comparison of ST segment elevation between before administration of streptokinase (4.01mm) and 90 min after administration of streptokinase (1.5mm), the ST segment resolution was seen after thrombolysis and the difference was statistically significant (p<0.0001) (Figure 3 ). In present study, the overall success rate of thrombolysis 65.84% is reported. Similarly a study by Anuj R Verma, Swapnil Chillawar, et al. they have also followed the same method to predict the successful clinical outcomes and 60% of the subjects have with successful clinical reperfusion. 10 Another study by Rolf Schröder, et.al, they have found that extent of ST segment elevation that hypertension is highly prevalent in India.
14 Smoking (41.33%) was the second most reported parameter, then diabetics (37.33%) and alcoholics are (33%) respectively. These each risk factor was compared with changes in coronary pain resolution and ST segment resolution. Majority of the study subjects (96%) had pain resolution of ≥50%, after thrombolysis with streptokinase, same as, 72% of the study subjects had ≥50% ST segment resolution after thrombolysis with streptokinase. Though, Hypertension is reported as a prevalent risk factor, it has shown an paradoxic effect that, hypertensive subjects has shown with higher ST segment resolution than in non-hypertensive subjects, this point is collaborated with the study conducted by Yun Lin, Weiqi Pan et al. in china, they have found the same paradoxic effect with the hypertension. 15 The same condition is also repeated with diabetes, the diabetic subjects have shown higher ST segment resolution, when compared with nondiabetics, the similar paradoxic effect was also found in the study performed by Krinsley JS and Fischer M. 16 Another observation that, we have found from the present study that, the number of female subjects 6 (37.5%) and male subjects 21 (36%) with diabetes mellitus are almost equal in percentage, this statement is conjoined with a study on diabetes in STEMI, they have also got the similar results that chances of STEMI resolution conveys useful early information about the outcome in an individual patient after acute myocardial infarction. 11 And a similar study by James A de lemos and Eugene Braunwald, assessement of ST segment resolution even earlier than 3-4 h after onset of fibrinolytic therapy, can be used for risk stratification. 12 The study group consisted of 75 subjects which included 59 (78.7%) males and 16 (21.3%) female subjects. The mean age of male subjects was 54 years and the female subjects was 56.625 years. Most of the subjects are male (78.7%) and the mean of age is higher in female which was 56.625 years. similar observation has found by aygul N, Ozdenir K et al. in turkish patients in central Anatolia, in their study, the percentage of female patients increased with increasing age and 80% of the study subjects are male. 13 Each risk factor was studied (Diabetes mellitus, hypertension, smoking, alcohol and body mass index). Majority of the study subjects consumed mixed diet 90.67% and only 9.33% were vegetarians. Among the study subjects, 44% were hypertensives, 41.33% were smokers, 37.33% were diabetics, 36% were alcoholics and 20% were overweight and obese subjects. Further 21.33% of study subjects had a family history of CAD. Hypertension (44%) was highly reported among study subject, in associated with another study on hypertension, they have also described Most of the study subjects (96%) had pain resolution of ≥50% after thrombolysis with streptokinase. However, there is no statistically significant association between pain variation beforestreptokinase administration and 90 minutes after streptokinase administration with each risk factor studied (diabetes mellitus, hypertension, smoking, alcohol and body mass index). Majority of the study subjects (72%) had ST segment resolution of ≥50% after thrombolysis with streptokinase. It was observed that a higher proportion of diabetics (78.58%) and hypertensives (73.54%) had ST segment resolution of ≥50% when compared to non-diabetics and non-hypertensives. There is no statistically significant association observed between ST segment resolution before streptokinase administration and 90 minutes after streptokinase administration with each of this risk factors studied (diabetes mellitus, hypertension, smoking, alcohol and body mass index).
are almost equal in both male and female. 17 In present study, smoking is reported as a second major risk factor. The non-smokers have shown a higher pain and ST segment resolution than in smokers, it has been describing that smoking can be the major impact on STEMI, a global study have also described the similar statement that, non-smokers are more beneficial than smokers on thrombolytic therapy. 18 Likewise, non-alcoholics have shown higher pain and ST segment resolution than alcoholics, consumption of alcohol can affect the thrombolytic therapy.
CONCLUSION
In conclusion, our study has shown a higher number of males as compared with females, presenting with acute myocardial infarction. Hypertension and smoking form the most common risk factors, seen in 44% and 41/% of the patients respectively. Diabetes mellitus was seen in 37% of the subjects. There is a significant pain resolution (p<0.0001) with streptokinase administration. There is a significant resolution in ST elevation (p<0.0001) following streptokinase administration. Given the high efficacy, wider availability, lower cost and fewer haemorrhagic complications, it can be concluded that streptokinase can be used as a first time thrombolysis in our country. 19 
